Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging-Market Specialist Nycomed Acquires Majority Stake In China's Guangdong Techpool Bio-Pharma

This article was originally published in PharmAsia News

Executive Summary

Following through on a goal to expand operations in one of the world's fastest growing markets, Nycomed AS confirmed Nov. 1 that it is beefing up its Chinese presence through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma

You may also be interested in...



Takeda's China Development Remains In CRO Hands

Takeda said there is "difficulty" in determining how a China research unit would fit into its global R&D program.

A Closer Look: Alogliptin's Delay Accelerated Takeda's Pursuit Of Nycomed

Takeda found itself desperate to fill gaps with Actos LOE looming and alogliptin faltering, hastening a 10-year conversation with Nycomed.

A Closer Look: Alogliptin's Delay Accelerated Takeda's Pursuit Of Nycomed

Takeda found itself desperate to fill gaps with Actos LOE looming and alogliptin faltering, hastening a 10-year conversation with Nycomed.

Related Content

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel